Consistently, treatment of mice with ATXN3-null tumors with anti–PD-1 at the suboptimal dose of 50 μg nearly totally rejected the tumor (Figure 5, C–E), implying a synergistic effect of ATXN3 inhibition and anti–PD-1 therapy. This evidence concerns the gene PDCD1 and neoplasm.